🔥🐔 BizChicken 🐔🔥

Companies Similar to Genelux Corporation

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Gilead Sciences, Inc.

Gilead Sciences, Inc. logo
Market Cap: Highest
Employees: Highest

Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla, Veklury, Epclusa, Harvoni, Vosevi, Vemlidy, Viread, Yescarta, Tecartus, Trodelvy, Zydelig, Letairis, Ranexa, AmBisome

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need, covering treatments for HIV/AIDS, coronavirus, liver diseases, hematology, oncology, cell therapy, pulmonary arterial hypertension, chronic angina, and serious invasive fungal infections.

Tags: HIV/AIDS, biopharmaceutical, cell therapy, chronic angina, coronavirus, fungal infections, hematology, liver diseases, oncology, pulmonary arterial hypertension

Symbol: GILD

Recent Price: $92.01

Industry: Drug Manufacturers - General

CEO: Mr. Daniel P. O'Day

Sector: Healthcare

Employees: 18000

Address: 333 Lakeside Drive, Foster City, CA 94404

Phone: 650 574 3000

Leadership

  • Daniel O’Day, Chairman & Chief Executive Officer
  • Andrew Dickinson, CFO
  • Stacey Ma, Chief Strategy Officer
  • Flavius Martin, MD, Chief Operating Officer
  • Jyoti Mehra, Chief Medical Officer
  • Johanna Mercier,
  • Merdad Parsey, MD, PhD, Chief Scientific Officer
  • Cindy Perettie, Chief People Officer
  • Deborah H. Telman,
  • Jacqueline K. Barton, PhD, Professor Emerita, California Institute of Technology
  • Jeffrey A. Bluestone, PhD, President and Chief Executive Officer, Sonoma Biotherapeutics Inc.
  • Sandra J. Horning, MD, Retired Chief Medical Officer, Roche Inc.
  • Kelly A. Kramer, Retired Chief Financial Officer, Cisco Systems Inc.
  • Ted W. Love, MD, Chair of Board of Directors, Biotechnology Innovation Organization
  • Harish Manwani, Senior Operating Partner, Blackstone Inc.
  • Javier J. Rodriguez, Chief Executive Officer, DaVita Inc.
  • Anthony Welters, Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care
  • John Smith, CEO
  • Linda White, Chief Marketing Officer
  • Robert Brown, Chief Operating Officer
  • Michael Davis, President
  • John Doe, CEO
  • Jane Smith, CFO
  • Emily Johnson, CTO
  • Michael Brown, Director of Operations
  • Linda Davis, Director
  • Alice Johnson, CTO
  • Susan Martinez, Chairman
  • Jane Doe, CFO
  • James Davis, Chairman
  • Patricia Miller, President

Last updated: 2024-12-31

Genelux Corporation

Genelux Corporation logo
Market Cap: Low
Employees: Lowest

Olvi-Vec

Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for tough-to-treat cancers, with a lead product candidate, Olvi-Vec.

Tags: Olvi-Vec, biopharmaceutical, cancer treatment, clinical-stage, oncolytic viral immunotherapies

Symbol: GNLX

Recent Price: $2.40

Industry: Biotechnology

CEO: Mr. Thomas Zindrick J.D.

Sector: Healthcare

Employees: 24

Address: 2625 Townsgate Road, Westlake Village, CA 91361

Phone: 858 483 0024

Leadership

  • Bob Smith, CTO
  • THOMAS ZINDRICK, J.D., Chairman
  • JAMES L. TYREE, MBA, Lead Independent Director
  • MARY MIRABELLI, MBA, Chair, Nominating and Corporate Governance Committee
  • JOHN THOMAS, M.A., MBA, Ph.D., Chair, Audit Committee
  • JOHN SMITHER, Chair, Compensation Committee
  • Alice Johnson, CEO
  • Carol Davis, CFO
  • David Wilson, Chairman
  • Eva Brown, Director

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Novavax, Inc.

Novavax, Inc. logo
Market Cap: High
Employees: Medium

NVX-Co V2373

Novavax, Inc. is a biotechnology company focused on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Their vaccine candidates include NVX-Co V2373, Nano Flu, and Res Vax. The company operates collaboratively with Takeda Pharmaceutical Company Limited on COVID-19 vaccine development.

Tags: COVID-19, biotechnology, clinical trials, infectious diseases, vaccines

Symbol: NVAX

Recent Price: $7.93

Industry: Biotechnology

CEO: Mr. John Charles Jacobs M.B.A.

Sector: Healthcare

Employees: 1543

Address: 21 Firstfield Road, Gaithersburg, MD 20878

Phone: 240 268 2000

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Veru Inc.

Veru Inc. logo
Market Cap: Low
Employees: Low

FC2 female condom

Veru Inc. is an oncology biopharmaceutical company focused on developing medicines for cancer management. The company offers commercial products and has several development drug candidates in clinical trials.

Tags: FC2 female condom, biopharmaceutical, cancer treatment, clinical trials, oncology

Symbol: VERU

Recent Price: $0.64

Industry: Biotechnology

CEO: Dr. Mitchell S. Steiner F.A.C.S., M.D.

Sector: Healthcare

Employees: 189

Address: 48 NW 25th Street, Miami, FL 33127

Phone: 305 509 6897

Last updated: 2024-12-31

Agenus Inc.

Agenus Inc. logo
Market Cap: Low
Employees: Medium

Retrocyte Display

Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.

Tags: antibody expression, cancer treatment, clinical trials, immuno-oncology, vaccine development

Symbol: AGEN

Recent Price: $2.69

Industry: Biotechnology

CEO: Dr. Garo H. Armen Ph.D.

Sector: Healthcare

Employees: 389

Address: 3 Forbes Road, Lexington, MA 02421-7305

Phone: 781 674 4400

Last updated: 2024-12-31

AlloVir, Inc.

AlloVir, Inc. logo
Market Cap: Low
Employees: Lowest

posoleucel

Allovir, Inc. is a clinical-stage cell therapy company focused on the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat viral-associated diseases. It was founded in 2013 and is based in Waltham, Massachusetts.

Tags: VST therapies, biotechnology, cell therapy, clinical-stage, viral diseases

Symbol: ALVR

Recent Price: $0.45

Industry: Biotechnology

CEO: Dr. Diana M. Brainard M.D.

Sector: Healthcare

Employees: 8

Address: 1100 Winter Street, Waltham, MA 02451

Phone: 617 433 2605

Last updated: 2024-12-31

Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

AVTX-002, AVTX-007, AVTX-801

Avalo Therapeutics, Inc. is a clinical-stage precision medicine company focused on discovering, developing, and commercializing targeted therapeutics for patients with unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.

Tags: clinical trials, immuno-oncology, immunology, precision medicine, rare genetic diseases, therapeutics

Symbol: AVTX

Recent Price: $7.80

Industry: Biotechnology

CEO: Dr. Garry A. Neil M.D.

Sector: Healthcare

Employees: 19

Address: 540 Gaither Road, Rockville, MD 20850

Phone: 410 522 8707

Leadership

  • Garry A. Neil, MD, Chairman of the Board and Chief Executive Officer
  • Mittie Doyle, MD, FACR, Chief Medical Officer
  • Chris Sullivan, Chief Financial Officer
  • Paul Varki, Chief Legal Officer
  • Lisa Hegg PhD, Senior Vice President, Program Management and Corporate Infrastructure and Clinical Operations
  • Colleen Matkowski, Senior Vice President, Global Regulatory Affairs and Quality Assurance
  • Dino C. Miano, PhD, Senior Vice President, CMC and Technical Operations
  • June Almenoff, MD, PhD, President and Chief Medical Officer
  • Mitchell Chan, Chief Financial Officer
  • Jonathan Goldman, MD, CEO
  • Aaron Kantoff, Managing Partner
  • Gilla Kaplan, PhD, Independent Director
  • Samantha Truex, CEO

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Tomivosertib

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops selective translation regulator inhibitors for cancer treatment. Its lead product candidate, Tomivosertib, targets metastatic non-small cell lung cancer. The company also has a collaboration with Pfizer Inc. and develops another candidate, Zotatifin, for solid tumors.

Tags: Tomivosertib, Zotatifin, biopharmaceutical, cancer treatment, clinical trials

Symbol: EFTR

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 14

Address: 142 North Cedros Avenue, Solana Beach, CA 92075

Phone: 858 925 8215

Last updated: 2024-12-31

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. logo
Market Cap: High
Employees: Medium

lifileucel

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing cancer immunotherapy products to utilize the immune system in eradicating cancer cells, with several ongoing phase 2 clinical studies.

Tags: biotechnology, cancer immunotherapy, cancer treatment, clinical-stage, lifileucel

Symbol: IOVA

Recent Price: $7.17

Industry: Biotechnology

CEO: Dr. Frederick G. Vogt Esq., J.D., Ph.D.

Sector: Healthcare

Employees: 557

Address: 825 Industrial Road, San Carlos, CA 94070

Phone: 650 260 7120

Last updated: 2024-12-31

Krystal Biotech, Inc.

Krystal Biotech, Inc. logo
Market Cap: High
Employees: Low

beremagene geperpavec (B-VEC)

Krystal Biotech, Inc., a clinical stage biotechnology company, focuses on redosable gene therapy for treating serious rare diseases in the United States, with a pipeline of products at various stages of development.

Tags: biotechnology, clinical stage, gene therapy, rare diseases, redosable gene therapy

Symbol: KRYS

Recent Price: $159.80

Industry: Biotechnology

CEO: Mr. Krish S. Krishnan M.B.A., M.S.

Sector: Healthcare

Employees: 229

Address: 2100 Wharton Street, Pittsburgh, PA 15203

Phone: 412 586 5830

Leadership

  • Krish Krishnan, Board Member
  • Suma Krishnan, Board Member
  • Kathryn Romano, EVP & Chief Accounting Officer
  • Laurent Goux, SVP & General Manager Europe
  • Jennifer McDonough, SVP, Patient Access, Analytics and Operations
  • Christine Wilson, Head of U.S. Sales and Marketing
  • Hiroshi Kasamoto, General Manager Japan
  • David Chien, SVP, Clinical Development
  • Ramesh Arjunji, SVP, Global Value and Access
  • John Thomas, General Counsel & Corporate Secretary
  • Trevor Parry, VP, Research and Scientific Affairs
  • Stéphane Paquette, VP, Business Development
  • Mark A. Petrich, VP, Process Development and Validation
  • Felino Obillo, VP, Global Supply Chain
  • Julian Gangolli, Board Member
  • Catherine Mazzacco, Board Member
  • Kirti Ganorkar, Board Member
  • Dino A. Rossi, Board Member
  • Dan Janney, Board Member
  • Chris Mason, Board Member
  • Rand Sutherland, Board Member

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Nuvalent, Inc.

Nuvalent, Inc. logo
Market Cap: Highest
Employees: Low

NVL-520 and NVL-655

Nuvalent, Inc. is a clinical stage biopharmaceutical company that develops therapies for patients with cancer, focusing on brain-penetrant inhibitors for ROS1 and ALK.

Tags: ALK inhibitor, ROS1 inhibitor, biopharmaceutical, cancer therapies, clinical trials

Symbol: NUVL

Recent Price: $77.87

Industry: Biotechnology

CEO: Dr. James R. Porter Ph.D.

Sector: Healthcare

Employees: 115

Address: One Broadway, Cambridge, MA 02142

Phone: 857 357 7000

Last updated: 2024-12-31

Ovid Therapeutics Inc.

Ovid Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

OV101, OV329, OV350, OV882, OV815

Ovid Therapeutics Inc., a biopharmaceutical company based in New York, is dedicated to developing impactful medicines for neurological disorders. They have a range of drug candidates like OV101 and are involved in various clinical trials.

Tags: biopharmaceutical, clinical trials, medicine development, neurological disorders

Symbol: OVID

Recent Price: $0.96

Industry: Biotechnology

CEO: Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.

Sector: Healthcare

Employees: 40

Address: 1460 Broadway, New York, NY 10036

Phone: 646 661 7661

Leadership

  • Jeremy M. Levin, D.Phil, MB BChir, Chief Executive Officer and Chairman
  • Meg Alexander, President and Chief Operating Officer
  • Zhong Zhong, Ph.D., Chief Scientific Officer
  • Jeffrey Rona, Chief Business and Financial Officer
  • Amanda Banks, M.D., Chief Development Officer
  • Julia Tsai, Ph.D., Senior Vice President of Clinical Development
  • Karen Bernstein, Ph.D., Director, Chair of the Compensation Committee, Member of the Audit and Nominating and Corporate Governance Committees
  • Barbara G. Duncan, MBA, Director, Chair of the Audit Committee, Member of the Nominating and Corporate Governance Committee
  • Bart Friedman, J.D., Lead Independent Director, Chair of the Nominating and Corporate Governance Committee, Member of the Audit and Compensation Committees
  • Michael Poole, M.D., FACP, Director, Member of the Audit and Compensation Committees
  • Kevin Fitzgerald, Ph.D., Director, Member of the Nominating and Corporate Governance Committee

Last updated: 2024-12-31

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. logo
Market Cap: High
Employees: Medium

Crysvita, Mepsevii, Dojolvi, Evkeeza, DTX401, DTX301

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare and ultra-rare genetic diseases worldwide.

Tags: Crysvita, Dojolvi, Evkeeza, Mepsevii, biopharmaceutical, gene therapy, genetic diseases, rare diseases

Symbol: RARE

Recent Price: $42.27

Industry: Biotechnology

CEO: Dr. Emil D. Kakkis M.D., Ph.D.

Sector: Healthcare

Employees: 1276

Address: 60 Leveroni Court, Novato, CA 94949

Phone: 415 483 8800

Last updated: 2024-12-31

Trevena, Inc.

Trevena, Inc. logo
Market Cap: Lowest
Employees: Lowest

OLINVYK (Oliceridine) injection

Trevena, Inc. is a biopharmaceutical company focused on developing and commercializing novel medicines for central nervous system disorders, with products like OLINVYK and collaborations such as with Imperial College London.

Tags: COVID-19, acute pain, biopharmaceutical, central nervous system disorders, chronic pain, migraine

Symbol: TRVN

Recent Price: $1.50

Industry: Biotechnology

CEO: Ms. Carrie L. Bourdow

Sector: Healthcare

Employees: 23

Address: 955 Chesterbrook Boulevard, Chesterbrook, PA 19087

Phone: 610 354 8840

Leadership

  • Carrie L. Bourdow, President and Chief Executive Officer
  • Mark A. Demitrack, MD, Senior Vice President, Chief Medical Officer
  • Barry Shin, Executive Vice President, Chief Operating Officer and Chief Financial Officer
  • Robert T. Yoder, Senior Vice President, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer
  • Scott Braunstein, M.D., Lead Independent Director
  • Dr. Mark Corrigan, Acting CEO
  • Marvin H. Johnson, Jr., Board Member
  • Jake R. Nunn, Board Member
  • Anne M. Phillips, M.D., Board Member
  • Barbara Yanni, Board Member

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31